-
1
-
-
84923808557
-
Biomarkers: Exceptional responders-discovering predictive biomarkers
-
N. Takebe, L. McShane, and B. Conley Biomarkers: exceptional responders-discovering predictive biomarkers Nat Rev Clin Oncol 12 3 2015 132 134
-
(2015)
Nat Rev Clin Oncol
, vol.12
, Issue.3
, pp. 132-134
-
-
Takebe, N.1
McShane, L.2
Conley, B.3
-
2
-
-
84901829381
-
Learning from exceptional drug responders
-
A. Mullard Learning from exceptional drug responders Nat Rev Drug Discov 13 6 2014 401 402
-
(2014)
Nat Rev Drug Discov
, vol.13
, Issue.6
, pp. 401-402
-
-
Mullard, A.1
-
3
-
-
84973667267
-
NCI starts 'exceptional responder' hunt
-
A. Mullard NCI starts 'exceptional responder' hunt Nat Rev Drug Discov 13 11 2014 803
-
(2014)
Nat Rev Drug Discov
, vol.13
, Issue.11
, pp. 803
-
-
Mullard, A.1
-
4
-
-
84941118318
-
In search of exceptional responders
-
In search of exceptional responders Cancer Discov 5 1 2015 8
-
(2015)
Cancer Discov
, vol.5
, Issue.1
, pp. 8
-
-
-
5
-
-
84921024765
-
Cancer centers zero in on exceptional responders
-
Erratum in Nat Biotechnol. 2014;32(11):1074. Dosage error in article text
-
C. Sheridan Cancer centers zero in on exceptional responders Nat Biotechnol 32 8 2014 703 704 Erratum in Nat Biotechnol. 2014;32(11):1074. Dosage error in article text
-
(2014)
Nat Biotechnol
, vol.32
, Issue.8
, pp. 703-704
-
-
Sheridan, C.1
-
6
-
-
84928403539
-
Cancer: A most exceptional response
-
V. Marx Cancer: a most exceptional response Nature 520 7547 2015 389 393
-
(2015)
Nature
, vol.520
, Issue.7547
, pp. 389-393
-
-
Marx, V.1
-
7
-
-
84887462642
-
"n of 1" case reports in the era of whole-genome sequencing
-
A.R. Brannon, and C.L. Sawyers "N of 1" case reports in the era of whole-genome sequencing J Clin Invest 123 11 2013 4568 4570
-
(2013)
J Clin Invest
, vol.123
, Issue.11
, pp. 4568-4570
-
-
Brannon, A.R.1
Sawyers, C.L.2
-
8
-
-
84899645673
-
Mining the genomes of exceptional responders
-
D.K. Chang, S.M. Grimmond, T.R. Evans, and A.V. Biankin Mining the genomes of exceptional responders Nat Rev Cancer 14 5 2014 291 292
-
(2014)
Nat Rev Cancer
, vol.14
, Issue.5
, pp. 291-292
-
-
Chang, D.K.1
Grimmond, S.M.2
Evans, T.R.3
Biankin, A.V.4
-
10
-
-
84907863603
-
Response and acquired resistance to everolimus in anaplastic thyroid cancer
-
N. Wagle, B.C. Grabiner, E.M. Van Allen, and et al. Response and acquired resistance to everolimus in anaplastic thyroid cancer N Engl J Med 371 15 2014 1426 1433
-
(2014)
N Engl J Med
, vol.371
, Issue.15
, pp. 1426-1433
-
-
Wagle, N.1
Grabiner, B.C.2
Van Allen, E.M.3
-
12
-
-
79959627009
-
-
Clinical case of the month. A patient with advanced non-small-cell lung cancer presenting with an exceptional response to targeted therapies [in French]
-
A.S. Thonnard, L. Bosquee, and J.L. Corhay Clinical case of the month. A patient with advanced non-small-cell lung cancer presenting with an exceptional response to targeted therapies [in French] Rev Med Liege 66 3 2011 121 125
-
(2011)
Rev Med Liege
, vol.66
, Issue.3
, pp. 121-125
-
-
Thonnard, A.S.1
Bosquee, L.2
Corhay, J.L.3
-
13
-
-
84940501179
-
Remarkable response to crizotinib in woman with anaplastic lymphoma kinase-rearranged anaplastic thyroid carcinoma
-
Y. Godbert, B. Henriques de Figueiredo, F. Bonichon, and et al. Remarkable response to crizotinib in woman with anaplastic lymphoma kinase-rearranged anaplastic thyroid carcinoma J Clin Oncol 33 20 2015 e84 e87
-
(2015)
J Clin Oncol
, vol.33
, Issue.20
, pp. e84-e87
-
-
Godbert, Y.1
Henriques De Figueiredo, B.2
Bonichon, F.3
-
14
-
-
84978022583
-
Radium-223 dichloride bone-targeted alpha particle therapy for hormone-refractory breast cancer metastatic to bone
-
A. Takalkar, S. Adams, and V. Subbiah Radium-223 dichloride bone-targeted alpha particle therapy for hormone-refractory breast cancer metastatic to bone Exp Hematol Oncol 3 2014 23
-
(2014)
Exp Hematol Oncol
, vol.3
, pp. 23
-
-
Takalkar, A.1
Adams, S.2
Subbiah, V.3
-
15
-
-
84909589393
-
Dramatic response to dabrafenib and trametinib combination in a BRAF V600E-mutated cholangiocarcinoma: Implementation of a molecular tumour board and next-generation sequencing for personalized medicine
-
A. Loaiza-Bonilla, E. Clayton, E. Furth, M. O'Hara, and J. Morrissette Dramatic response to dabrafenib and trametinib combination in a BRAF V600E-mutated cholangiocarcinoma: implementation of a molecular tumour board and next-generation sequencing for personalized medicine Ecancermedicalscience 8 2014 479
-
(2014)
Ecancermedicalscience
, vol.8
, pp. 479
-
-
Loaiza-Bonilla, A.1
Clayton, E.2
Furth, E.3
O'Hara, M.4
Morrissette, J.5
-
16
-
-
84869206991
-
Targeting the apoptotic pathway in chondrosarcoma using recombinant human Apo2L/TRAIL (dulanermin), a dual proapoptotic receptor (DR4/DR5) agonist
-
V. Subbiah, R.E. Brown, J. Buryanek, and et al. Targeting the apoptotic pathway in chondrosarcoma using recombinant human Apo2L/TRAIL (dulanermin), a dual proapoptotic receptor (DR4/DR5) agonist Mol Cancer Ther 11 11 2012 2541 2546
-
(2012)
Mol Cancer Ther
, vol.11
, Issue.11
, pp. 2541-2546
-
-
Subbiah, V.1
Brown, R.E.2
Buryanek, J.3
-
17
-
-
84904304127
-
Induction of sustained deep molecular response in a patient with chronic-phase T315I-mutated chronic myeloid leukemia with interferon-alpha monotherapy
-
M. Ilander, P. Koskenvesa, S. Hernesniemi, T. Lion, K. Porkka, and S. Mustjoki Induction of sustained deep molecular response in a patient with chronic-phase T315I-mutated chronic myeloid leukemia with interferon-alpha monotherapy Leuk Lymphoma 55 4 2014 934 937
-
(2014)
Leuk Lymphoma
, vol.55
, Issue.4
, pp. 934-937
-
-
Ilander, M.1
Koskenvesa, P.2
Hernesniemi, S.3
Lion, T.4
Porkka, K.5
Mustjoki, S.6
-
18
-
-
79953742425
-
Targeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: Response/resistance signatures
-
V. Subbiah, A. Naing, R.E. Brown, and et al. Targeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: response/resistance signatures PLoS One 6 4 2011 e18424
-
(2011)
PLoS One
, vol.6
, Issue.4
, pp. e18424
-
-
Subbiah, V.1
Naing, A.2
Brown, R.E.3
-
19
-
-
84908288657
-
Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent(R)) a VEGFR2/PDGFRbeta/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial
-
V. Subbiah, F. Meric-Bernstam, G.B. Mills, and et al. Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent(R)) a VEGFR2/PDGFRbeta/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial J Hematol Oncol 7 2014 52
-
(2014)
J Hematol Oncol
, vol.7
, pp. 52
-
-
Subbiah, V.1
Meric-Bernstam, F.2
Mills, G.B.3
-
20
-
-
84994493627
-
Genomic correlate of exceptional erlotinib response in head and neck squamous cell carcinoma
-
E.M. Van Allen, V.W. Lui, A.M. Egloff, and et al. Genomic correlate of exceptional erlotinib response in head and neck squamous cell carcinoma JAMA Oncol 1 2 2015 238 244
-
(2015)
JAMA Oncol
, vol.1
, Issue.2
, pp. 238-244
-
-
Van Allen, E.M.1
Lui, V.W.2
Egloff, A.M.3
-
21
-
-
84893823864
-
A novel immunomodulatory molecularly targeted strategy for refractory Hodgkin's lymphoma
-
V. Subbiah, R.E. Brown, M.F. McGuire, and et al. A novel immunomodulatory molecularly targeted strategy for refractory Hodgkin's lymphoma Oncotarget 5 1 2014 95 102
-
(2014)
Oncotarget
, vol.5
, Issue.1
, pp. 95-102
-
-
Subbiah, V.1
Brown, R.E.2
McGuire, M.F.3
-
22
-
-
84922254940
-
Immune activation and a 9-year ongoing complete remission following CD40 antibody therapy and metastasectomy in a patient with metastatic melanoma
-
D.L. Bajor, X. Xu, D.A. Torigian, and et al. Immune activation and a 9-year ongoing complete remission following CD40 antibody therapy and metastasectomy in a patient with metastatic melanoma Cancer Immunol Res 2 11 2014 1051 1058
-
(2014)
Cancer Immunol Res
, vol.2
, Issue.11
, pp. 1051-1058
-
-
Bajor, D.L.1
Xu, X.2
Torigian, D.A.3
-
23
-
-
38449097977
-
Mini-dose of thalidomide for treatment of primary myelofibrosis. Report of a case with complete reversal of bone marrow fibrosis and splenomegaly
-
A. Berrebi, E. Feldberg, I. Spivak, and L. Shvidel Mini-dose of thalidomide for treatment of primary myelofibrosis. Report of a case with complete reversal of bone marrow fibrosis and splenomegaly Haematologica 92 2 2007 e15 e16
-
(2007)
Haematologica
, vol.92
, Issue.2
, pp. e15-e16
-
-
Berrebi, A.1
Feldberg, E.2
Spivak, I.3
Shvidel, L.4
-
24
-
-
84908363886
-
Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer
-
C.M. Lovly, N.T. McDonald, H. Chen, and et al. Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer Nat Med 20 9 2014 1027 1034
-
(2014)
Nat Med
, vol.20
, Issue.9
, pp. 1027-1034
-
-
Lovly, C.M.1
McDonald, N.T.2
Chen, H.3
-
25
-
-
84874459104
-
Salvage surgery for a super-responder by gefitinib therapy for advanced lung cancer
-
K. Hashimoto, H. Horinouchi, T. Ohtsuka, and et al. Salvage surgery for a super-responder by gefitinib therapy for advanced lung cancer Gen Thorac Cardiovasc Surg 60 12 2012 851 854
-
(2012)
Gen Thorac Cardiovasc Surg
, vol.60
, Issue.12
, pp. 851-854
-
-
Hashimoto, K.1
Horinouchi, H.2
Ohtsuka, T.3
-
26
-
-
84857090723
-
Phase i study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors
-
A.I. Daud, S.S. Krishnamurthi, M.N. Saleh, and et al. Phase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors Clin Cancer Res 18 4 2012 1092 1100
-
(2012)
Clin Cancer Res
, vol.18
, Issue.4
, pp. 1092-1100
-
-
Daud, A.I.1
Krishnamurthi, S.S.2
Saleh, M.N.3
-
27
-
-
84860524932
-
A phase i pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class i selective histone deacetylase inhibitor in refractory solid tumors
-
U. Banerji, L. van Doorn, D. Papadatos-Pastos, and et al. A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors Clin Cancer Res 18 9 2012 2687 2694
-
(2012)
Clin Cancer Res
, vol.18
, Issue.9
, pp. 2687-2694
-
-
Banerji, U.1
Van Doorn, L.2
Papadatos-Pastos, D.3
-
28
-
-
77649215630
-
Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: Targeting the pathogenic activation of mTORC1 in tumors
-
A.J. Wagner, I. Malinowska-Kolodziej, J.A. Morgan, and et al. Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors J Clin Oncol 28 5 2010 835 840
-
(2010)
J Clin Oncol
, vol.28
, Issue.5
, pp. 835-840
-
-
Wagner, A.J.1
Malinowska-Kolodziej, I.2
Morgan, J.A.3
-
29
-
-
84866301785
-
Durable remission of leptomeningeal metastases from hormone-responsive prostate cancer
-
M. Zhang, A. Mahta, R.Y. Kim, S. Akar, and S. Kesari Durable remission of leptomeningeal metastases from hormone-responsive prostate cancer Med Oncol 29 2 2012 806 808
-
(2012)
Med Oncol
, vol.29
, Issue.2
, pp. 806-808
-
-
Zhang, M.1
Mahta, A.2
Kim, R.Y.3
Akar, S.4
Kesari, S.5
-
30
-
-
84898732516
-
Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy
-
M.H. Voss, A.A. Hakimi, C.G. Pham, and et al. Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy Clin Cancer Res 20 7 2014 1955 1964
-
(2014)
Clin Cancer Res
, vol.20
, Issue.7
, pp. 1955-1964
-
-
Voss, M.H.1
Hakimi, A.A.2
Pham, C.G.3
-
31
-
-
84906903083
-
Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy
-
H. Al-Ahmadie, G. Iyer, M. Hohl, and et al. Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy Cancer Discov 4 9 2014 1014 1021
-
(2014)
Cancer Discov
, vol.4
, Issue.9
, pp. 1014-1021
-
-
Al-Ahmadie, H.1
Iyer, G.2
Hohl, M.3
-
32
-
-
84892379425
-
Targeted therapy by combined inhibition of the RAF and mTOR kinases in malignant spindle cell neoplasm harboring the KIAA1549-BRAF fusion protein
-
V. Subbiah, S.N. Westin, K. Wang, and et al. Targeted therapy by combined inhibition of the RAF and mTOR kinases in malignant spindle cell neoplasm harboring the KIAA1549-BRAF fusion protein J Hematol Oncol 7 2014 8
-
(2014)
J Hematol Oncol
, vol.7
, pp. 8
-
-
Subbiah, V.1
Westin, S.N.2
Wang, K.3
-
33
-
-
84942989099
-
Exceptional response to pazopanib in a patient with urothelial carcinoma harboring FGFR3 activating mutation and amplification
-
N. Palma, J.C. Morris, S.M. Ali, J.S. Ross, and S.K. Pal Exceptional response to pazopanib in a patient with urothelial carcinoma harboring FGFR3 activating mutation and amplification Eur Urol 68 1 2015 168 170
-
(2015)
Eur Urol
, vol.68
, Issue.1
, pp. 168-170
-
-
Palma, N.1
Morris, J.C.2
Ali, S.M.3
Ross, J.S.4
Pal, S.K.5
-
34
-
-
84929999263
-
Exceptional response on addition of everolimus to taxane in urothelial carcinoma bearing an NF2 mutation
-
S.M. Ali, V.A. Miller, J.S. Ross, and S.K. Pal Exceptional response on addition of everolimus to taxane in urothelial carcinoma bearing an NF2 mutation Eur Urol 67 6 2015 1195 1196
-
(2015)
Eur Urol
, vol.67
, Issue.6
, pp. 1195-1196
-
-
Ali, S.M.1
Miller, V.A.2
Ross, J.S.3
Pal, S.K.4
-
35
-
-
84899680978
-
Activating mTOR mutations in a patient with an extraordinary response on a phase i trial of everolimus and pazopanib
-
N. Wagle, B.C. Grabiner, E.M. Van Allen, and et al. Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib Cancer Discov 4 5 2014 546 553
-
(2014)
Cancer Discov
, vol.4
, Issue.5
, pp. 546-553
-
-
Wagle, N.1
Grabiner, B.C.2
Van Allen, E.M.3
-
36
-
-
84867333656
-
Genome sequencing identifies a basis for everolimus sensitivity
-
G. Iyer, A.J. Hanrahan, M.I. Milowsky, and et al. Genome sequencing identifies a basis for everolimus sensitivity Science 338 6104 2012 221
-
(2012)
Science
, vol.338
, Issue.6104
, pp. 221
-
-
Iyer, G.1
Hanrahan, A.J.2
Milowsky, M.I.3
-
37
-
-
84982893727
-
Five years of cancer drug approvals: Innovation, efficacy, and costs
-
S. Mailankody, and V. Prasad Five years of cancer drug approvals: innovation, efficacy, and costs JAMA Oncol 1 4 2015 539 540
-
(2015)
JAMA Oncol
, vol.1
, Issue.4
, pp. 539-540
-
-
Mailankody, S.1
Prasad, V.2
-
38
-
-
55249092961
-
Surgery and radiotherapy improves survival in patients with anaplastic thyroid carcinoma: Analysis of the surveillance, epidemiology, and end results 1983-2002
-
J. Chen, J.D. Tward, D.C. Shrieve, and Y.J. Hitchcock Surgery and radiotherapy improves survival in patients with anaplastic thyroid carcinoma: analysis of the surveillance, epidemiology, and end results 1983-2002 Am J Clin Oncol 31 5 2008 460 464
-
(2008)
Am J Clin Oncol
, vol.31
, Issue.5
, pp. 460-464
-
-
Chen, J.1
Tward, J.D.2
Shrieve, D.C.3
Hitchcock, Y.J.4
-
39
-
-
79958043675
-
-
National Cancer Institute seer.cancer.gov Web site. Accessed September 10, 2015
-
National Cancer Institute. SEER cancer statistics review 1975-2012. seer.cancer.gov Web site. http://seer.cancer.gov/csr/1975-2012/results-merged/sect-22-pancreas.pdf. Accessed September 10, 2015.
-
SEER Cancer Statistics Review 1975-2012
-
-
-
40
-
-
84961708815
-
-
aboutcancer.com Web site. Accessed September 10, 2015
-
Survival statistics for cancer of the pancreas. aboutcancer.com Web site. http://www.aboutcancer.com/pancreas3.htm. Accessed September 10, 2015.
-
Survival Statistics for Cancer of the Pancreas
-
-
-
41
-
-
84892701195
-
The accelerated approval of oncologic drugs: Lessons from ponatinib
-
V. Prasad, and S. Mailankody The accelerated approval of oncologic drugs: lessons from ponatinib JAMA 311 4 2014 353 354
-
(2014)
JAMA
, vol.311
, Issue.4
, pp. 353-354
-
-
Prasad, V.1
Mailankody, S.2
-
42
-
-
0020590588
-
Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia
-
M. Talpaz, K.B. McCredie, G.M. Mavligit, and J.U. Gutterman Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia Blood 62 3 1983 689 692
-
(1983)
Blood
, vol.62
, Issue.3
, pp. 689-692
-
-
Talpaz, M.1
McCredie, K.B.2
Mavligit, G.M.3
Gutterman, J.U.4
-
43
-
-
84876100195
-
Re-emergence of interferon-α in the treatment of chronic myeloid leukemia
-
M. Talpaz, R. Hehlmann, A. Quintás-Cardama, J. Mercer, and J. Cortes Re-emergence of interferon-α in the treatment of chronic myeloid leukemia Leukemia 27 4 2013 803 812
-
(2013)
Leukemia
, vol.27
, Issue.4
, pp. 803-812
-
-
Talpaz, M.1
Hehlmann, R.2
Quintás-Cardama, A.3
Mercer, J.4
Cortes, J.5
-
44
-
-
84928582479
-
Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity
-
D.V. Catenacci Next-generation clinical trials: novel strategies to address the challenge of tumor molecular heterogeneity Mol Oncol 9 5 2015 967 996
-
(2015)
Mol Oncol
, vol.9
, Issue.5
, pp. 967-996
-
-
Catenacci, D.V.1
-
45
-
-
84928503242
-
What have we learned from exceptional tumour responses? Review and perspectives
-
N. Mehra, D. Lorente, and J.S. de Bono What have we learned from exceptional tumour responses? Review and perspectives Curr Opin Oncol 27 3 2015 267 275
-
(2015)
Curr Opin Oncol
, vol.27
, Issue.3
, pp. 267-275
-
-
Mehra, N.1
Lorente, D.2
De Bono, J.S.3
-
46
-
-
84927154472
-
Basket trials and the evolution of clinical trial design in an era of genomic medicine
-
A.J. Redig, and P.A. Jänne Basket trials and the evolution of clinical trial design in an era of genomic medicine J Clin Oncol 33 9 2015 975 977
-
(2015)
J Clin Oncol
, vol.33
, Issue.9
, pp. 975-977
-
-
Redig, A.J.1
Jänne, P.A.2
-
47
-
-
84880991913
-
'Basket studies' will hold intricate data for cancer drug approvals
-
C. Willyard 'Basket studies' will hold intricate data for cancer drug approvals Nat Med 19 6 2013 655
-
(2013)
Nat Med
, vol.19
, Issue.6
, pp. 655
-
-
Willyard, C.1
-
48
-
-
78649932986
-
The mean does not mean as much anymore: Finding subgroups for tailored therapeutics
-
S.J. Ruberg, L. Chen, and Y. Wang The mean does not mean as much anymore: finding subgroups for tailored therapeutics Clin Trials 7 5 2010 574 583
-
(2010)
Clin Trials
, vol.7
, Issue.5
, pp. 574-583
-
-
Ruberg, S.J.1
Chen, L.2
Wang, Y.3
-
49
-
-
84939825159
-
The strength of association between surrogate end points and survival in oncology: A systematic review of trial-level meta-analyses
-
V. Prasad, C. Kim, M. Burotto, and A. Vandross The strength of association between surrogate end points and survival in oncology: a systematic review of trial-level meta-analyses JAMA Intern Med 175 8 2015 1389 1398
-
(2015)
JAMA Intern Med
, vol.175
, Issue.8
, pp. 1389-1398
-
-
Prasad, V.1
Kim, C.2
Burotto, M.3
Vandross, A.4
-
50
-
-
84927606243
-
Lung Master Protocol (Lung-MAP) - A biomarker-driven protocol for accelerating development of therapies for squamous cell lung cancer: SWOG S1400
-
R.S. Herbst, D.R. Gandara, F.R. Hirsch, and et al. Lung Master Protocol (Lung-MAP) - a biomarker-driven protocol for accelerating development of therapies for squamous cell lung cancer: SWOG S1400 Clin Cancer Res 21 7 2015 1514 1524
-
(2015)
Clin Cancer Res
, vol.21
, Issue.7
, pp. 1514-1524
-
-
Herbst, R.S.1
Gandara, D.R.2
Hirsch, F.R.3
|